3-allylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-allylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
• 英文别名: 3-Allylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide；6-chloro-1,1-dioxo-N-prop-2-enyl-4H-thieno[3,2-e][1,2,4]thiadiazin-3-imine
• 化学式: C₈H₈ClN₃O₂S₂
• 分子量: 277.755
• InChiKey: MRXBHKOVCZAFML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  天然芥菜籽油 、 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride 生成 3-allylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
  参考文献：
  名称：

  Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their

  摘要：

  本发明涉及一种由以下式子表示的1,2,4-噻二嗪和1,4-噻二嗪衍生物：##STR1## 其中A，B，D，R.sup.1，R.sup.2，R.sup.3和R.sup.4在说明书中有定义，描述了它们的组成和制备方法。这些化合物在治疗中枢神经系统、心血管系统、肺系统、胃肠系统和内分泌系统的疾病中有用。

  公开号：

  US05889002A1

文献信息

• Use of potassium channel agonists for the treatment of cancer
  申请人：——

  公开号：US20020028808A1

  公开（公告）日：2002-03-07

  The present invention relates to the use of potassium channel agonists for treating cancer, more particular the treatment and/or prevention of breast cancer and endometrial cancer. The present invention also embraces the use of the compounds of general formulas (I) and (Ia) in treating cancer and methods of using the compounds and their pharmaceutical compositions.

  本发明涉及使用钾通道激动剂治疗癌症，更具体地说是治疗和/或预防乳腺癌和子宫内膜癌。本发明还包括使用一般式(I)和(Ia)的化合物治疗癌症以及使用这些化合物及其药物组合物的方法。
• Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
  申请人：University of Maryland, Baltimore

  公开号：EP2359832A2

  公开（公告）日：2011-08-24

  The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, agonists and antagonists of the NCCA-ATP channel are contemplated. The therapeutic compositions are used to treat cancer, more specifically, a metastatic brain tumor, wherein a tumor-brain barrier is present. Such treatments are contemplated in combination with conventional anti-cancer therapies. Alternatively, the compositions are used to prevent cell death and to treat cerebral edema that result from ischemia, due to interruption of blood flow, to tissue trauma or to increased tissue pressure.

  本发明涉及针对星形胶质细胞、神经元或毛细血管内皮细胞的 NCCa-ATP 通道的治疗组合物及其使用方法。更具体地说，考虑使用 NCCA-ATP 通道的激动剂和拮抗剂。治疗组合物用于治疗癌症，更具体地说，治疗存在肿瘤-脑屏障的转移性脑肿瘤。这种治疗可考虑与传统的抗癌疗法相结合。另外，组合物还可用于防止细胞死亡和治疗因血流中断、组织创伤或组织压力增加而导致的缺血性脑水肿。
• Therapeutic methods that target the NCCA-ATP channel
  申请人：Simard J. Marc

  公开号：US10583094B2

  公开（公告）日：2020-03-10

  The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, agonists and antagonists of the NCCa-ATP channel are contemplated. The therapeutic compositions are used to treat cancer, more specifically, a metastatic brain tumor, wherein a tumor-brain barrier is present. Such treatments are contemplated in combination with conventional anti-cancer therapies. Alternatively, the compositions are used to prevent cell death and to treat cerebral edema that result from ischemia, due to interruption of blood flow, to tissue trauma or to increased tissue pressure.

  本发明涉及针对星形胶质细胞、神经元或毛细血管内皮细胞的 NCCa-ATP 通道的治疗组合物及其使用方法。更具体地说，考虑使用 NCCa-ATP 通道的激动剂和拮抗剂。治疗组合物用于治疗癌症，更具体地说，治疗存在肿瘤-脑屏障的转移性脑肿瘤。这种治疗可考虑与传统的抗癌疗法相结合。另外，组合物还可用于防止细胞死亡和治疗因血流中断、组织创伤或组织压力增加而导致的缺血性脑水肿。
• Use of potassium channel agonists for reducing fat food consumption
  申请人：——

  公开号：US20020035106A1

  公开（公告）日：2002-03-21

  The present invention relates to the use of potassium channel agonists for reducing or lowering the consumption of fat food. The present invention also embraces the use of the compounds of general formulas (I) and (Ia) in reducing or lowering the intake of fat food and methods of using the compounds and their pharmaceutical compositions.

  本发明涉及使用钾通道激动剂减少或降低脂肪食物的摄入量。本发明还包括通式（I）和（Ia）化合物在减少或降低脂肪食物摄入量方面的用途，以及使用这些化合物及其药物组合物的方法。
• Use of selective potassium channel openers
  申请人：——

  公开号：US20030125323A1

  公开（公告）日：2003-07-03

  The present invention relates to a use of SUR1/Kir6.2 selective potassium channel openers for the preparation of a pharmaceutical composition for the prevention or the treatment of diabetes, and for the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome (PCOS) as well as a pharmaceutical composition for use in the prevention or the treatment of diabetes, and in the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome.

  本发明涉及利用 SUR1/Kir6.2 选择性钾通道开放剂制备一种药物组合物，用于预防或治疗糖尿病，以及治疗多囊卵巢综合征（PCOS）女性患者的高胰岛素血症和高雄激素症，还涉及一种药物组合物，用于预防或治疗糖尿病，以及治疗多囊卵巢综合征女性患者的高胰岛素血症和高雄激素症。